Carmignac Gestion Reduces Position in Align Technology, Inc. $ALGN

Posted by Francis Steltz on Aug 3rd, 2026

Carmignac Gestion trimmed its position in Align Technology, Inc. (NASDAQ:ALGN – Free Report) by 8.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 225,171 shares of the medical equipment provider’s stock after selling 20,930 shares during the quarter. Carmignac Gestion owned approximately 0.31% of Align Technology worth $38,537,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ALGN. Blue Trust Inc. increased its holdings in Align Technology by 77.5% in the first quarter. Blue Trust Inc. now owns 158 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 69 shares during the last quarter. Sunbelt Securities Inc. raised its stake in Align Technology by 222.4% in the fourth quarter. Sunbelt Securities Inc. now owns 158 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 109 shares in the last quarter. Independence Bank of Kentucky lifted its holdings in Align Technology by 77.7% during the 4th quarter. Independence Bank of Kentucky now owns 183 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 80 shares during the last quarter. CYBER HORNET ETFs LLC purchased a new stake in Align Technology during the 2nd quarter worth about $36,000. Finally, Tobam acquired a new position in shares of Align Technology during the 4th quarter worth about $30,000. 88.43% of the stock is owned by hedge funds and other institutional investors.

Align Technology News Summary

Here are the key news stories impacting Align Technology this week:

Positive Sentiment: Q2 results exceeded expectations. Align reported adjusted earnings of $2.64 per share and revenue of approximately $1.06 billion, topping consensus estimates. Revenue increased 4.3% year over year, while record Clear Aligner shipments and improved non-GAAP margins supported profitability. Align Technology Q2 Earnings and Revenues Top Estimates
Positive Sentiment: Digital orthodontics remains a growth focus. Management highlighted expanding digital workflows, connected orthodontic tools and long-term opportunities for Invisalign, iTero scanners and exocad software. The company’s 2026 outlook was reaffirmed, while an orthodontic summit showcased its product and technology strategy. ALGN Q2 Earnings Call Highlights Digital Growth Push
Positive Sentiment: Board changes could improve shareholder value. Following discussions with Elliott Investment Management, Align plans to add three independent directors and conduct an operational review. The initiatives may increase accountability, improve execution and identify opportunities to enhance returns. Align Technology to Overhaul Board Following Engagement with Elliott
Neutral Sentiment: Valuation is viewed as more attractive after the pullback. Some analysts see ALGN as reasonably valued, but believe the stock needs faster growth to generate sustained upside. Align Technology: Attractively Valued, But Growth Still Needs To Pick Up
Negative Sentiment: Near-term guidance and execution remain concerns. Third-quarter revenue guidance of roughly $1.0 billion was described as slightly below or around expectations, limiting the benefit of the earnings beat.
Negative Sentiment: Systems weakness is capping upside. Analysts noted softer scanner and systems performance, along with pricing pressure, despite strong Clear Aligner volumes. Needham maintained a Hold rating. Align Technology Hold Rating Maintained
Negative Sentiment: Growth is still relatively modest. Investors may remain cautious because revenue growth has not yet accelerated enough to justify a more bullish outlook, even with improving margins and record aligner shipments.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. UBS Group reiterated a “neutral” rating and issued a $189.00 price objective on shares of Align Technology in a report on Thursday, July 23rd. Wall Street Zen downgraded Align Technology from a “strong-buy” rating to a “buy” rating in a report on Saturday. Morgan Stanley upped their price target on Align Technology from $169.00 to $188.00 and gave the company an “equal weight” rating in a report on Friday, April 24th. Weiss Ratings upgraded shares of Align Technology from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 17th. Finally, Citigroup assumed coverage on shares of Align Technology in a report on Wednesday, April 15th. They set a “buy” rating and a $240.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Align Technology currently has an average rating of “Moderate Buy” and a consensus price target of $206.36.

Read Our Latest Research Report on ALGN

Align Technology Stock Performance

ALGN opened at $169.16 on Monday. The business’s 50-day simple moving average is $174.55 and its 200-day simple moving average is $175.23. Align Technology, Inc. has a one year low of $122.00 and a one year high of $200.43. The stock has a market capitalization of $12.12 billion, a P/E ratio of 29.42, a price-to-earnings-growth ratio of 1.78 and a beta of 1.65.

Align Technology (NASDAQ:ALGN – Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.02. The firm had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Align Technology had a return on equity of 15.86% and a net margin of 9.99%.The business’s revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.49 EPS. On average, equities research analysts forecast that Align Technology, Inc. will post 9.48 EPS for the current fiscal year.

Align Technology declared that its Board of Directors has approved a share repurchase plan on Wednesday, April 29th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 1.6% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Align Technology Company Profile

(Free Report)

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.